BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 07, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Veliparib: Phase II data

In 24 evaluable patients in a Phase II trial, veliparib plus Temodar temozolomide produced 1 complete response, 2 partial responses and 7 cases of stable disease. Patients received 40 mg twice-daily oral veliparib...

Read the full 153 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >